3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Endocrine
1
Conditions
Neuroendocrine Tumors
1
Carcinoma, Neuroendocrine
1
Carcinoid Tumor
1
Interventions
Nivolumab
5
atezolizumab
3
Ipilimumab
3
cabozantinib
2
Temozolomide
2
Immunoglobulin G
2
Disulfides
2
Cisplatin
2
Carboplatin
2
pembrolizumab
1
niraparib
1
lutetium Lu 177 dotatate
1
dostarlimab
1
budigalimab
1
Topotecan
1
Specimen Handling
1
Radiosurgery
1
Magnetic Resonance Spectroscopy
1
Irinotecan
1
Etoposide
1
Capecitabine
1
CTLA-4 Antigen
1
Biopsy
1
Bevacizumab
1
BAY 1895344
1
177Lu-octreotate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Carcinoma, Neuroendocrine
×
177Lu-octreotate
×
Clear all
NCT02754297
2024-08-21
P-PRRT
CHU de Quebec-Universite Laval
Phase 2
Active not recruiting
275 enrolled